FAKTOR OPTIONSSCHEIN - GILEAD SCIENCES | Delayed Deutsche Boerse AG 01:20:45 2024-06-20 pm EDT | ||
| 0.26 EUR | -29.73% |
|
| Current month | +2.78% | ||
| 1 month | +19.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 0.26 | -29.73% |
| 24-06-19 | 0.37 | +2.78% |
| 24-06-18 | 0.36 | +5.88% |
| 24-06-17 | 0.34 | 0.00% |
| 24-06-14 | 0.34 | -8.11% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 01:20 pm EDT
More quotesStatic data
| Product type | Warrant Esotici e Strutturati |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PF3G1S |
| ISIN | DE000PF3G1S2 |
| Date issued | 2020-02-27 |
| Strike | 63.15 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.56 € |
|---|---|
| Lowest since issue | 0.162 € |
| Spread | 0.01 € |
| Spread % | 3.57% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.15
USD
Average target price
82.7
USD
Spread / Average Target
+30.95%
- Stock Market
- Certificates
- Certificat
